newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

  • IGC Pharma reported Q2 FY 2026 financial results & accelerated its Phase 2 CALMA trial for IGC-AD1, achieving over 50% patient enrollment.
  • The company divested a non-core Vancouver manufacturing facility for $2.7 million, booking a $1.1 million non-cash profit & eliminating $600,000 in annual operating expenses.
  • IGC received a special award from the National Institute on Aging (NIA) recognizing excellence in code clarity, reproducibility, & usability for its AI-driven Alzheimer's detection.
  • Preclinical data for the multi-pathway small-molecule candidate IGC-M3 showed promise in targeting amyloid aggregation, mitochondrial dysfunction, & neuroinflammation.
  • R&D expenses increased by 73% to $1.6 million to reflect accelerated clinical trial progress & preclinical asset advancement.
  • Other net income surged 2,407% to $1.2 million, primarily driven by the non-cash profit from the facility divestiture.
  • Net loss per share remained stable at $0.02 despite the significant rise in R&D investment.
  • Shareholders approved increasing authorized common stock from 150 million to 600 million to support future financing & partnerships.
  • No draws were taken on the $12 million Credit Agreement with O-Bank as of September 30, 2025, preserving liquidity.
  • Revenue decreased 54% to approximately $191,000 due to the planned transition period associated with the manufacturing facility disposition.
  • The USPTO issued a Notice of Allowance for patent application IGC510 covering methods to treat stammering, stuttering, or Tourette's syndrome.
  • Future strategic priorities include completing CALMA trial enrollment, piloting the MINT-AD AI diagnostic platform, advancing IGC-M3, & evaluating strategic partnerships.